Technology Report

No Image

Release: Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinson’s Disease

November 28, 2012 OneMedPlace Team 0

Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson’s disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has successfully completed experiments demonstrating that MANF has an excellent diffusion profile in the striatum of rat brains.

No Image

Diagnostics: Biomarkers, Gene Patents, and Personalized Medicine in Jeopardy

November 19, 2012 OneMedPlace Team 1

Fallout from the the US Supreme Court landmark decision to deny two patents to Prometheus Laboratories may complicate the future profitability of the industry. If this is indeed a precedent-setting decision, biomarker patents may now fall under the realm of “law of nature”, cutting off the prospect of exclusive market penetration that once justified the significant research and development onus in the early stages.

No Image

OneMedRadio: DARA BioSciences CEO on Oncology Market Opportunity, Key Catalysts

November 9, 2012 OneMedPlace Team 0

In Part II of our discussion with DARA Biosciences (NASDAQ: DARA) CEO and Chief Medical Officer Dr. David Drutz, we look into key catalysts for the specialty pharmaceutical company. Dr. Drutz discusses the medical need for the oral-liquid tamoxifen, Soltamox, licensed to DARA by UK-based Rosemont Pharmaceuticals — as well as the market opportunity in developing oncology services.

No Image

BIOTECH 2012: Panel of CEOs — Lather, Rinse, Repeat

October 26, 2012 Lisa Sher 0

Hosted by BioNJ, Pennsylvania Bio and Delaware Bio, their three word mission: “Find. Fund. Facilitate.” was clearly accomplished. Networking is still an integral part of these cerebral gatherings, however programming at this conference provided attendees with candid information, stimulating conversation and a new perspective on the industry.

No Image

CEVEC Pharmaceuticals GmbH Raises € 2.8MM in Series C Financing

October 26, 2012 OneMedPlace Team 0

CEVEC Pharmaceuticals GmbH (CEVEC), the developer of a novel human expression system for the manufacturing of complex biopharmaceuticals and vaccines announced today that it raised an additional amount of € 2.8 million in a Series C financing led by Peppermint VenturePartners (PVP) via the new Charité Biomedical Fund.

No Image

OneMedRadio: Healthtech Conference 2012 — What to Watch For

October 15, 2012 OneMedPlace Team 0

HealthTech Conference 2012, on October 26th in San Francisco, is a single day summit covering the most important issues in this burgeoning sector. OneMedRadio spoke with Anne Degheest, Managing Director and Founder of HealthTech Capital, about conference programming, and the unique investment opportunity in the sector.